Heron Therapeutics | HRTX - Заемный капитал





Заемный капитал Изменить Дата
ALKERMES USD 1.48B 1.2B 2026-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
ANI Pharmaceuticals USD 286M 5.84M 2026-03
Arrowhead Research USD 1.23B 687.3M 2026-03
Eisai JPY 134.78B 12M 2026-03
Emergent BioSolutions USD 446.5M 1.7M 2023-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Insmed USD 542.22M 1.25M 2026-03
Ligand Pharmaceuticals USD 446.19M 702K 2025-12
Merck USD 46.67B 77M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Omeros USD 403.72M 27.2M 2024-06
Pacira USD 367.66M 4.53M 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Veracyte USD 0 0 2025-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12